Triethanolamine Salicylate

Generic Name: triethanolamine salicylate

Over-the-Counter (OTC)

Brand Names:

Salicor

DESCRIPTION Salicor™ is an external analgesic product containing 10% triethanolamine salicylate as the active ingredient. Triethanolamine salicylate is an organic compound formed between triethanolamine and salicylic acid, where triethanolamine neutralizes the acidity of salicylic acid. This external analgesic is designed for temporary relief of minor pain associated with arthritis, simple backache, muscle strains, sprains, and bruises.

Overview

DESCRIPTION Salicor™ is an external analgesic product containing 10% triethanolamine salicylate as the active ingredient. Triethanolamine salicylate is an organic compound formed between triethanolamine and salicylic acid, where triethanolamine neutralizes the acidity of salicylic acid. This external analgesic is designed for temporary relief of minor pain associated with arthritis, simple backache, muscle strains, sprains, and bruises.

Uses

INDICATION AND USAGE Salicor™ is indicated for the temporary relief of minor aches and pains of muscles and joints associated with: arthritis, simple backache, muscle strains and sprains, bruises, bursitis, and dysmenorrhea. Salicor™ provides a localized analgesic effect directly at the site of pain, offering convenience and sustained relief compared to cream formulations.

Dosage

DOSAGE AND ADMINISTRATION For adults 18 years and older: • Clean and dry the affected area • Locate the tear notch on the edge of the pouch. Tear open at the notch or carefully cut open the pouch with scissors, taking care not to cut the system inside • Remove the transparent release liner before applying Salicor™ to the skin • Apply one Salicor™ to the affected area of pain and leave it in place for 8 to 12 hours • Apply only one Salicor™ at a time • If pain persists, the used Salicor™ may be replaced with a new one for up to 8 to 12 more hours • Always remove and properly dispose of the used Salicor™ before applying a new one • Salicor™ may be cut into smaller sizes with scissors prior to removing the release liner • Safely discard the used Salicor™ (whole or cut pieces) where children a...

Interactions

Drugs That May Cause Methemoglobinemia When Used with Salicor™ Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Examples of Drugs Associated with Methemoglobinemia Class: Nitrates/Nitrites: Local anesthetics: Antineoplastic agents: Antibiotics: Antimalarials: Anticonvulsants: Other drugs: Examples: nitric oxide, nitroglycerin, nitroprusside, nitrous oxide articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides chloroquine, primaquine phenobarbital, phenytoin, sodium v...

Warnings

PRECAUTIONS General If irritation or a burning sensation occurs during application, wash the product off your skin and do not reapply until the irritation subsides. When Salicor™ is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered. Stop use and ask a doctor if • Condition worsens • Symptoms persist for more than 7 days, or symptoms return within a few days after discontinuing use • Redness is present • Irritation develops Hepatic Disease Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of triethanolamine salicylate because of their inability to metabolize triethanolamine salicylate normally.

Pregnancy

Pregnancy Before taking NSAIDs, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant. Taking NSAIDs at about 20 weeks of pregnancy or later may harm your unborn baby. If you need to take NSAIDs for more than 2 days when you are between 20 and 30 weeks of pregnancy, your healthcare provider may need to monitor the amount of fluid in your womb around your baby. You should not take NSAIDs after about 30 weeks of pregnancy. Pregnancy Category B. Salicor™ has not been studied in pregnancy.

Storage

STORAGE AND HANDLING Avoid contact with the eyes. Keep away from excessive heat and direct sunlight. Salicor™ should be kept out of reach of children. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]

Frequently Asked Questions

What is Triethanolamine Salicylate used for?

INDICATION AND USAGE Salicor™ is indicated for the temporary relief of minor aches and pains of muscles and joints associated with: arthritis, simple backache, muscle strains and sprains, bruises, bursitis, and dysmenorrhea. Salicor™ provides a localized analgesic effect directly at the site of pain, offering convenience and sustained relief compared to cream formulations.

Can I take Triethanolamine Salicylate during pregnancy?

Pregnancy Before taking NSAIDs, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant. Taking NSAIDs at about 20 weeks of pregnancy or later may harm your unborn baby. If you need to take NSAIDs for more than 2 days when you are between 20 and 30 weeks of pregnancy, your healthcare provider may need to monitor the amount of fluid in your womb around your baby. You should not take NSAIDs after about 30 weeks of pregnancy. Pregnancy Category B. Salicor™ has not been studied in pregnancy.

What are the important warnings for Triethanolamine Salicylate?

PRECAUTIONS General If irritation or a burning sensation occurs during application, wash the product off your skin and do not reapply until the irritation subsides. When Salicor™ is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered. Stop use and ask a doctor if • Condition worsens • Symptoms persist for more than 7 days, or symptoms return within a few days after discontinuing use • Redness is present • Irritation develops Hepatic Disease Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of triethanolamine salicylate because of their inability to metabolize triethanolamine salicylate normally.

Related Medications

Medical Disclaimer

This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.